AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17513184
Drug: Antenatal magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal magnesium sulphate therapy
Trial: 17513184
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antenatal magnesium sulphate therapy)
Trial: 7786657
Drug: Felodipine 2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 2.5-10 mg twice daily
Trial: 6504944
Drug: Pentoxifylline ('Trental'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline ('Trental' 400) 400 mg (2 tablets)
Trial: 30451531
Drug: Light force
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light force (300 g) CHG
Trial: 30451531
Drug: Heavy force
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy force (500 g) CHG
Trial: 16493167
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block with ropivacaine and oral hydrocodone
Trial: 16493167
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of bupivacaine/morphine and oral oxycodone
Trial: 9072885
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (Actiferrin, 3 x 1 cps/d, 724.5 mg elemental Fe per week)
Trial: 9072885
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation (Ferrum-Lek, 1 vial per week, 100 mg elemental iron per week)
Trial: 1306677
Drug: Oral-B 35
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B 35 manual toothbrush
Trial: 3866334
Drug: Xylocaine 5%
RxNorm normalized name: Xylocaine 5% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylocaine 5% ointment
Trial: 25022705
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of IPL-F and LF-QS-Nd:YAG laser
Trial: 21438412
Drug: Naoxinduotai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxinduotai capsule + perindopril
Trial: 12107665
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily (stratified by age 64 years)
Trial: 12107665
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily (stratified by age 76 years)
Trial: 10023618
Drug: Network Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Network Therapy (NT)
Trial: 7581086
Drug: FK506 (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day)
Trial: 1698845
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1 mg/kg methylprednisolone
Trial: 417377
Drug: Intramuscular loxapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular loxapine
Trial: 417377
Drug: Oral loxapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loxapine
Trial: 31743569
Drug: Ipragliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin (50 mg, once daily)
Trial: 31743569
Drug: Placebo (initially)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initially) then switched to Ipragliflozin (50 mg, once daily)
Trial: 22770818
Drug: Single sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single sterile water injection (n=147)
Trial: 22770818
Drug: Four sterile
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four sterile water injections (n=158)
Trial: 20396720
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of artrofoon and anaferon
Trial: 15114907
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two types of judgment with two stimulus dimensions
Trial: 11557191
Drug: Pyridoxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (100 mg/day)
Trial: 8269914
Drug: Folate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate (5 mg/day)
Trial: 9590462
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg taken orally once daily for 7 consecutive days
Trial: 9590462
Drug: Irbesartan administration
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan administration on day 1
Trial: 9590462
Drug: Irbesartan administration
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan administration on day 7
Trial: 7599468
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of i.v. antibiotics tobramycin
Trial: 7599468
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of i.v. antibiotics Timentin
Trial: 7599468
Drug: Flushing solution
RxNorm normalized name: WATER 985.77 g in 1000 mL TOPICAL SOLUTION [Eyewash Flushing Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flushing solution (both normal saline and heparinised saline)
Trial: 3279997
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance treatment (stopping MP)
Trial: 27999851
Drug: Placebo (Lecithin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Lecithin, 2400 mg daily)
Trial: 27999851
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (eicosapentaenoic acid (EPA); 1770 mg, and docosahexaenoic acid (DHA); 390 mg, daily)
Trial: 27999851
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1,000 IU daily)
Trial: 23791619
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg MK-7123
Trial: 16169314
Drug: Clopidogrel in
RxNorm normalized name: Product containing clopidogrel in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel in addition to low- to moderate-dose aspirin
Trial: 16169314
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to low- to moderate-dose aspirin
Trial: 14582907
Drug: Short-burst oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-burst oxygen therapy (SBOT) before exercise
Trial: 14582907
Drug: Short-burst oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-burst oxygen therapy (SBOT) after exercise
Trial: 10577444
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of ACE inhibitor dosage according to serial measurement of plasma BNP concentration (BNP group)
Trial: 10577444
Drug: Optimal empirical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal empirical ACE inhibitor therapy (clinical group)
Trial: 8735314
Drug: Contraceptive pill
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive pill
Trial: 7459218
Drug: Good-prognosis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good-prognosis group (BUC <= 8 mM, [Hb] >= 100 g/l, no or minimal symptoms)
Trial: 7459218
Drug: Poor-prognosis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor-prognosis group ([Hb] <= 75 g/l or BUC > 10 mM and restricted clinical activity)
Trial: 31108814
Drug: Synthesized oligopeptides;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthesized oligopeptides; specific peptides synthesized for confirmation and quantification; details on dosage and duration not available.
Trial: 16393735
Drug: Naltrexone (25/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (25/50 mg dd.) combined with nicotine replacement therapy (NRT) and Community Reinforcement Approach (CRA)
Trial: 16393735
Drug: Non-psychosocial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-psychosocial therapy group
Trial: 15289705
Drug: Lormetazepam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 0.03 mg/kg
Trial: 11397963
Drug: Daclizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (5 doses at biweekly intervals), 3 gm/day mycophenolate mofetil for the first 6 months and 2 gm thereafter, conventional corticosteroid therapy
Trial: 9431900
Drug: Amoxycillin 750
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Trial: 9431900
Drug: Amoxycillin 1000
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Trial: 9431900
Drug: Amoxycillin 750
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days
Trial: 9431900
Drug: Amoxycillin 1000
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days
Trial: 7904930
Drug: Propranolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (non-selective beta-blocker with no ISA)
Trial: 7904930
Drug: Pindolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (non-selective blocker with ISA)
Trial: 7904930
Drug: Metoprolol (beta-1-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta-1-selective blocker with ISA)
Trial: 29388815
Drug: Selepressin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selepressin (various dosing strategies)
Trial: 20588151
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1 mg/min for patients < 70 kg, 2 mg/min for patients ≥ 70 kg)
Trial: 20588151
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (0.125% and hydromorphone 6 microg/mL at 10 mL/hr)
Trial: 11708707
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.1 g x kg(‐1) lean body mass)
Trial: 7957514
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg every 12 h for three consecutive days
Trial: 7957514
Drug: Enoxacin 200
RxNorm normalized name: enoxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 200 mg every 8 h for three consecutive days
Trial: 3596867
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release tiaprofenic acid 600 mg once daily
Trial: 3596867
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet tiaprofenic acid 300 mg twice daily
Trial: 20169461
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (IVC) 0.5-1 g/m2 monthly for 6 months
Trial: 18205656
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral care (POC) by a dental hygienist
Trial: 16169891
Drug: Lidocaine 30
RxNorm normalized name: lidocaine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 30 mg and propofol 2.5 mg kg(‐1) (Group 1)
Trial: 16169891
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg kg(‐1) (Group 2)
Trial: 16169891
Drug: Lidocaine 30
RxNorm normalized name: lidocaine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 30 mg and thiopental 5 mg kg(‐1) (Group 3)
Trial: 16169891
Drug: Etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.3 mg kg(‐1) (Group 4)
Trial: 16169891
Drug: Lidocaine 30
RxNorm normalized name: lidocaine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 30 mg and etomidate 0.3 mg kg(‐1) (Group 5)
Trial: 15321934
Drug: BIS, SE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS, SE, RE during propofol infusion with remifentanil (Ce(REMI) 0, 2 or 4 ng ml(‐1))
Trial: 15321934
Drug: BIS, SE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS, SE, RE during propofol infusion without remifentanil (Ce(REMI) 0 ng ml(‐1))
Trial: 3671893
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) in fasting state
Trial: 3671893
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) with a protein-fat-rich breakfast
Trial: 3671893
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 a.m.
Trial: 3671893
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 p.m.
Trial: 3671893
Drug: Dosing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of 400, 800, and 1,200 mg of the ultrasustained-release theophylline preparation (Theo-1) for 3 days each in steady state
Trial: 8959115
Drug: Filgrastim as
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim as an adjunct to antibiotics for the treatment of CAP
Trial: 1307994
Drug: 30 nopal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 nopal capsules
Trial: 1307994
Drug: 30 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 placebo capsules
Trial: 1307994
Drug: 10 nopal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 nopal capsules t.i.d. for one week
Trial: 1307994
Drug: 10 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 placebo capsules t.i.d. for one week
Trial: 6698666
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium suppositories (equivalent to 500 mg naproxen)
Trial: 6698666
Drug: naproxen suppositories
RxNorm normalized name: naproxen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen suppositories (500 mg)
Trial: 6698666
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium suppositories
Trial: 6698666
Drug: naproxen suppositories
RxNorm normalized name: naproxen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen suppositories
Trial: 19621729
Drug: Postprandial 190
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial 190 mL black coffee
Trial: 16792761
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) treatment (585 nm)
Trial: 16792761
Drug: Calcipotriol/betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol/betamethasone dipropionate (Dovobet) treatment
Trial: 9412795
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg i.m. at 4-week intervals for 3 months)
Trial: 9412795
Drug: Leuprolide (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (3.75 mg s.c. at 4-week intervals for 3 months)
Trial: 9412795
Drug: Leuprolide (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (3.75 mg s.c.)
Trial: 7693419
Drug: Chemotherapy started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy started 12 weeks before surgery
Trial: 7693419
Drug: Therapy initiated
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy initiated shortly (perioperatively) after surgery
Trial: 2892430
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with lormetazepam (2 mg evening prior, 1 mg 2 hours prior) and propofol (2.4 mg/kg) with 70% nitrous oxide
Trial: 2892430
Drug: Propofol (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.4 mg/kg) with 70% nitrous oxide
Trial: 2892430
Drug: Additional i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional i.v. injection of fentanyl (3 micrograms/kg) prior to propofol
Trial: 2892430
Drug: No premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No premedication with lormetazepam and propofol (2.4 mg/kg) with 70% nitrous oxide
Trial: 25636519
Drug: Standard CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CC (single-rescuer group)
Trial: 22156354
Drug: Omeprazole 2
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2 x 20 mg and domperidone 3 x 10 mg for 2 weeks
Trial: 22156354
Drug: Omeprazole 2
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2 x 20 mg (control group)
Trial: 12212638
Drug: Haloperidol (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.04 mg/kg)
Trial: 8775995
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti‐gliadin IgG and anti‐endomysium IgA
Trial: 8775995
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti‐gliadin IgG and anti‐endomysium IgA plus anti‐gliadin IgA
Trial: 8775995
Drug: Early dietary
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early dietary treatment
Trial: 922756
Drug: CCNU (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCNU (100 mg/m2 orally every 6 weeks)
Trial: 922756
Drug: methyl-CCNU (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyl-CCNU (150 mg/m2 orally every 6 weeks)
Trial: 31335757
Drug: Discharge preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge preparation by individual nurses
Trial: 24735100
Drug: Insuman (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insuman (400 IU/mL)
Trial: 22398784
Drug: apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 5 mg orally
Trial: 22398784
Drug: enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 40 mg subcutaneously
Trial: 22398784
Drug: apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 5 mg and enoxaparin 40 mg concomitantly
Trial: 22398784
Drug: apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 5 mg followed 6 hours after by enoxaparin 40 mg
Trial: 9850403
Drug: Intrarectal Quinimax
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal Quinimax (20 mg/kg, then 15 mg/kg every 8 h for 2 days)
Trial: 9850403
Drug: Intravenous Quinimax
RxNorm normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Quinimax (8 mg/kg infused over 4 h every 8 h for 2 days)
Trial: 29861076
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment plus human albumin (HA) (40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months)
Trial: 29861076
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment plus human albumin (HA)
Trial: 16598777
Drug: Everolimus 0.5
RxNorm normalized name: everolimus 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 0.5 mg bid
Trial: 16598777
Drug: Everolimus 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.0 mg bid
Trial: 16598777
Drug: Everolimus 2
RxNorm normalized name: everolimus 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 2 mg bid
Trial: 8971430
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg administered orally after a standard breakfast
Trial: 8971430
Drug: Bumetanide 2
RxNorm normalized name: bumetanide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 2 mg administered orally after a standard breakfast